AnteoTech Limited (ASX:ADO)
Australia
· Delayed Price · Currency is AUD | Market Cap | 32.70M |
| Revenue (ttm) | 405.76K |
| Net Income (ttm) | -5.97M |
| Shares Out | 2.97B |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,525,285 |
| Average Volume | 893,347 |
| Open | 0.0110 |
| Previous Close | 0.0110 |
| Day's Range | 0.0100 - 0.0110 |
| 52-Week Range | 0.0070 - 0.0280 |
| Beta | 0.81 |
| RSI | 45.87 |
| Earnings Date | Feb 24, 2026 |
About AnteoTech
AnteoTech Limited develops, manufactures, commercializes, and distributes products for clean energy technology and life science markets primarily in Australia, Asia, Europe, and North America. The company’s products include AnteoBind, a metal-ion complex-based activation technology that offers an alternative to conventionally used chemistries for the life sciences industry; AnteoBind NXT solution for the development of diagnostic tests; AnteoBind Micro and Micro Kit, a micro-particle-based assay development and bioseparation; AnteoBind Sub-Micr... [Read more]
Financial Performance
In fiscal year 2025, AnteoTech's revenue was 968,878, an increase of 110.44% compared to the previous year's 460,397. Losses were -6.76 million, -23.89% less than in 2024.
Financial StatementsNews
AnteoTech Transcript: NWR Virtual Healthcare Conference
The business is focused on in vitro diagnostics, targeting new product development with AnteoBind NXT, and expanding into the chemiluminescence market. Strategic partnerships, increased sales efforts, and progress with a major life sciences company are key catalysts for growth in the next year.
AnteoTech Ltd (ASX:ADO) Half Year 2026 Earnings Call Highlights: Strategic Partnerships and ...
AnteoTech Ltd (ASX:ADO) Half Year 2026 Earnings Call Highlights: Strategic Partnerships and Market Expansion Amidst Revenue Challenges
Half Year 2026 Anteotech Ltd Earnings Call Transcript
Half Year 2026 Anteotech Ltd Earnings Call Transcript
AnteoTech Earnings Call Transcript: H1 2026
Streamlined operations and a successful AUD 3.5M capital raise have positioned the company for growth, with a strong sales pipeline in batteries and life sciences, and targeted expansion in the US, South Korea, and India.
AnteoTech Transcript: AGM 2025
The AGM highlighted strong revenue growth, successful product launches, and strategic expansion into new markets. All resolutions passed except the spill motion, with shareholders expressing confidence in the board and management's direction.
AnteoTech Earnings Call Transcript: H2 2025
Cost reductions and doubled revenue marked the year, with accelerated R&D rebates and strong commercial focus. High-silicon battery milestones and expanded global partnerships drive growth, while complex supply chains and long sales cycles remain key challenges.
AnteoTech Earnings Call Transcript: Q3 2025
A new CEO and board are leading a strategic review, focusing on commercializing battery and life sciences technologies. Market conditions remain challenging, but strong demand from the Serum Institute and global partnerships signal growth potential.
AnteoTech Ltd (ASX:ADO) (H1 2025) Earnings Call Highlights: Transition to Market-Driven Success
AnteoTech Ltd (ASX:ADO) (H1 2025) Earnings Call Highlights: Transition to Market-Driven Success
Half Year 2025 Anteotech Ltd Earnings Call Transcript
Half Year 2025 Anteotech Ltd Earnings Call Transcript
AnteoTech Earnings Call Transcript: H1 2025
Revenue rose 74% year-over-year with a 25% reduction in operating costs, driven by growth in both clean energy and life sciences. Commercial milestones are near, with strong progress in battery technology and Indian diagnostics.